Franklin Resources Inc. Reduces Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Franklin Resources Inc. decreased its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 24.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 184,027 shares of the company’s stock after selling 59,733 shares during the period. Franklin Resources Inc. owned about 0.64% of Krystal Biotech worth $28,830,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of KRYS. Wilmington Savings Fund Society FSB purchased a new stake in Krystal Biotech in the third quarter worth about $40,000. Avanza Fonder AB purchased a new stake in Krystal Biotech in the 4th quarter worth approximately $119,000. KBC Group NV raised its stake in Krystal Biotech by 46.3% during the 4th quarter. KBC Group NV now owns 939 shares of the company’s stock worth $147,000 after acquiring an additional 297 shares during the period. Blue Trust Inc. lifted its holdings in Krystal Biotech by 74.4% during the fourth quarter. Blue Trust Inc. now owns 1,015 shares of the company’s stock valued at $159,000 after purchasing an additional 433 shares in the last quarter. Finally, US Bancorp DE boosted its position in shares of Krystal Biotech by 8.7% in the fourth quarter. US Bancorp DE now owns 1,027 shares of the company’s stock worth $161,000 after purchasing an additional 82 shares during the period. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the sale, the insider now owns 1,463,711 shares of the company’s stock, valued at approximately $260,233,178.69. This represents a 1.68 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Kathryn Romano sold 750 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,604 shares of the company’s stock, valued at $2,208,472.88. This trade represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on KRYS. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Krystal Biotech in a research note on Thursday, February 20th. Chardan Capital upped their price objective on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th. Jefferies Financial Group started coverage on Krystal Biotech in a research note on Wednesday, March 5th. They set a “buy” rating and a $245.00 target price on the stock. Citigroup upped their price target on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research note on Thursday, February 20th. Finally, HC Wainwright reissued a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a report on Friday, February 28th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $220.00.

Krystal Biotech Price Performance

Shares of KRYS opened at $171.30 on Friday. The stock has a market capitalization of $4.93 billion, a price-to-earnings ratio of 57.29 and a beta of 0.75. The business’s 50 day simple moving average is $173.27 and its 200-day simple moving average is $173.07. Krystal Biotech, Inc. has a 1 year low of $141.72 and a 1 year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. During the same quarter in the prior year, the firm posted $0.30 earnings per share. The business’s revenue for the quarter was up 116.4% on a year-over-year basis. On average, sell-side analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).